AI antibody designer Chai Discovery closed a $130M Series B to scale its Chai‑2 generative platform for de novo antibody and full‑length mAb design. Chai reported double‑digit experimental success rates in preprints and claims rapid end‑to‑end design‑to‑validation cycles under two weeks. The financing will accelerate discovery projects, expand wet‑lab capacity and commercial efforts to offer AI‑driven antibody design as a platform service. The round underscores growing capital flows into generative AI startups targeting biologics design.